World CNS Summit South Korea
December 8 - 10, 2026 - KRHanson Wade
info@hansonwade.com
Phone:02031418700
Korea is rapidly emerging as a global hub for CNS innovation, with advances spanning diverse modalities, BBB shuttling technologies and differentiated targets beyond Amyloid beta and tau. As a result, pharma and venture interest has surged, with 2026 already witnessing major deals such as Fosun and AriBio, Insilico and SK Biopharmaceuticals and J and J and Prazer Therapeutics, highlighting the significant untapped potential to translate early-stage Korean assets into clinically successful, disease-modifying CNS therapies. Capitalizing on this skyrocketing investment and innovation momentum, the World CNS Summit South Korea will bring together Korean pioneers like ABL Bio, AriBio and ADEL, alongside international powerhouses including Eli Lilly, Lundbeck, JCR Pharmaceuticals and Novartis to exchange ideas and foster the collaborations needed to drive a new wave of disease-modifying neuroscience therapies. Time: 08:30 to 17:15